BCAB vs. CGEN, TSBX, CDTX, CLLS, LIFE, NSTG, JSPR, CCCC, ATHA, and CRDF
Should you be buying BioAtla stock or one of its competitors? The main competitors of BioAtla include Compugen (CGEN), Turnstone Biologics (TSBX), Cidara Therapeutics (CDTX), Cellectis (CLLS), aTyr Pharma (LIFE), NanoString Technologies (NSTG), Jasper Therapeutics (JSPR), C4 Therapeutics (CCCC), Athira Pharma (ATHA), and Cardiff Oncology (CRDF). These companies are all part of the "biological products, except diagnostic" industry.
Compugen (NASDAQ:CGEN) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings, community ranking and media sentiment.
Compugen currently has a consensus target price of $8.33, indicating a potential upside of 805.90%. BioAtla has a consensus target price of $14.83, indicating a potential upside of 882.34%. Given Compugen's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than Compugen.
13.3% of Compugen shares are owned by institutional investors. Comparatively, 71.7% of BioAtla shares are owned by institutional investors. 9.5% of Compugen shares are owned by company insiders. Comparatively, 8.4% of BioAtla shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
BioAtla's return on equity of -46.35% beat Compugen's return on equity.
Compugen received 283 more outperform votes than BioAtla when rated by MarketBeat users. Likewise, 65.15% of users gave Compugen an outperform vote while only 62.07% of users gave BioAtla an outperform vote.
Compugen has a beta of 2.66, suggesting that its share price is 166% more volatile than the S&P 500. Comparatively, BioAtla has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500.
Compugen has higher revenue and earnings than BioAtla. Compugen is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.
In the previous week, Compugen had 13 more articles in the media than BioAtla. MarketBeat recorded 13 mentions for Compugen and 0 mentions for BioAtla. Compugen's average media sentiment score of 0.94 beat BioAtla's score of 0.35 indicating that BioAtla is being referred to more favorably in the news media.
Summary
Compugen beats BioAtla on 10 of the 17 factors compared between the two stocks.
Get BioAtla News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools